Cardiovascular Disease

News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.

The polygenic score snags a greater percentage of people at risk of early heart attack than current tests that rely on single-gene variants or blood chemistry.

Investigators concluded that wearables show early promise in some cases, but there's limited evidence to substantiate claims of their ability to improve outcomes.

Investigators came up with a 182-variant risk score for early-onset coronary artery disease, which they tested on SNP data from UK Biobank participants with or without the condition.

Quest will have a broader relationship with Cleveland Clinic in diagnostic development, the companies say.

The company, which offers two tests for measuring the soluble ST2 protein in blood, will use the funding to continue global commercialization efforts.